Stoke Therapeutics vs Wave Life Sciences
STOK and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STOK and WVE compare
Stoke Therapeutics is the larger company, worth 2.8 times as much as Wave Life Sciences ($1.7B against $617M).
Wave Life Sciences keeps more of each dollar of sales as profit, with a net margin of −297% compared with −754% at Stoke Therapeutics.
Wave Life Sciences scores higher on the StockData Score (10 against 6 for Stoke Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STOK | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $617M |
| Share price | $26.68 | $3.13 |
| Change, 1 year | 6.2% | −55.0% |
| Change, 5 years | −4.0% | −27.4% |
| Beta (5Y) | 1.62 | 1.30 |
| Employees | 170 | 317 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 62.4× | 8.7× (better) |
| P/B | 5.0× | 1.5× (better) |
| FCF yield | −10.5% (better) | −33.8% |
| Fair value | $9.57 | $5.15 |
| Margin of safety | −179% | 39.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −86.2% | – |
| Revenue growth, 5Y average | – | 16.3% |
| Net income growth (TTM) | −496% | – |
| EPS growth (TTM) | −501% | – |
| Profitability | ||
| Operating margin | −810% | −321% (better) |
| Net margin | −754% | −297% (better) |
| FCF margin | −655% | −294% (better) |
| Return on equity | −61.1% (better) | −80.0% |
| Return on invested capital | −252% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −4856.0× | – |
| Current ratio | 7.69 | 8.38 (better) |
| Altman Z-score | 18.22 (better) | −0.98 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 120% | 92.6% |
| Held by insiders | 41.6% | 23.1% |
| Insider net buying, 12 months | −$6.7M | $66.5M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 28.5% | 13.6% |
Go deeper
- STOK stock overview
- STOK income statement
- STOK valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.